Telesis Bio

Telesis Bio Days Payable Outstanding

The Days Payable Outstanding (DPO) of Telesis Bio (TBIO) as of Oct 24, 2026 is 113.52. In the previous year, Days Payable Outstanding (DPO) was 39.92 — a change of 184.36% (higher).

Days Payable Outstanding

113.52

YoY

184.36%

Last updated:

Days Payable Outstanding (DPO) of Telesis Bio is 2023 113.52 . Days Payable Outstanding (DPO) of Telesis Bio was 2022 39.92 . It decreases by 184.36% higher compared to the previous year.

The Telesis Bio Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2019
25.21 USD
Jan 1, 2020
147.31 USD
Jan 1, 2021
135.25 USD
Jan 1, 2022
39.92 USD
Jan 1, 2023
113.52 USD
The Telesis Bio Days Payable Outstanding history
YEARDays Payable OutstandingYoY
113.52+184.36%
39.92-70.48%
135.25-8.19%
147.31+484.29%
25.21—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telesis Bio Stock analysis

What does Telesis Bio do? Codex DNA, Inc. develops genomic tools for biomedical and industrial applications, focusing on synthetic biology solutions to overcome bottlenecks in DNA and mRNA production. Its BioXp systems, including the BioXp 3250, serve as end-to-end automated workstations, while BioXp kits generate synthetic DNA and mRNA. The company offers 14 SARS-CoV-2 full-length genomes, RNA controls, and Vmax X2 cells as part of its product portfolio. BioXp systems are placed globally with approximately 200 units deployed. The firm targets researchers and biotech companies needing scalable DNA and mRNA synthesis, leveraging its automated workflow solutions. Products like BioXp kits and benchtop reagents complement the core systems, addressing limitations in current solutions. The company has launched eight BioXp kits and three benchtop reagent kits, supporting applications across biomedical and industrial sectors. Revenue streams come from selling BioXp systems, kits, and reagents directly to research institutions and biotechnology firms. The BioXp 3250 system, BioXp kits, and benchtop reagent kits are key products driving sales. Vmax X2 cells and SARS-CoV-2 related products also contribute to the company's revenue. Global deployment of 200 BioXp systems indicates strong market adoption among customers in the synthetic biology space. Telesis Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telesis Bio stock

Days Payable Outstanding (DPO) of Telesis Bio is 113.52 in 2023.

Days Payable Outstanding (DPO) of Telesis Bio changed from 39.92 to 113.52, representing a 184.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Telesis Bio since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Telesis Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Telesis Bio

All Key Metrics — Telesis Bio